Showing results (481-490 of 586) with videos related to

Sort By:
Pageof 59
Cancer|March 17, 2023
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancerKatherine I Foster, Kenna R M Shaw, Jeff Jin, et al.
Zootaxa|July 6, 2026
Note on Phalangopsidae crickets from Sabah and the Philippines, with description of a new species of LuzonogryllusMing Kai Tan, Ris Menoel R Modina, Joanna Rose A Alo, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unitDionysis Papadatos-Pastos, Desam Roda, Maria Jose De Miguel Luken, et al.
Molecular Cancer Therapeutics|April 29, 2010
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growthKyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, et al.
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
The Oncologist|July 21, 2021
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid TumorsKhanh T Do, Laura Quan Man Chow, Karen Reckamp, et al.
NPJ Precision Oncology|April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyJacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutationSarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.
NPJ Precision Oncology|January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD AndersonJeong Uk Lim, Heather Y Lin, Lei Kang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
Pageof 59